ADVANZ PHARMA

ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients’ lives by providing the specialty, hospital, and rare disease medicines they depend on. The company's ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. With commercial sales in more than 90 countries globally and a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, ADVANZ PHARMA's reach is extensive. The company's Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network, complement its global operations. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands covering a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and rare diseases. The last significant investment in ADVANZ PHARMA was a Post-IPO Equity investment on 26 February 2024 led by Nordic Capital and Ontario Teachers. This funding indicates a vote of confidence from established investors in the company's mission and potential for growth. With its extensive reach, diverse product portfolio, and recent investments, ADVANZ PHARMA presents an intriguing opportunity for venture capital seeking to make an impact in the health care and pharmaceutical industries.